Výsledky vyhledávání

Identification and structural elucidation of in vitro metabolites of atazanavir by HPLC and tandem mass spectrometry

Autor: Changfu, Cheng, Richard, Gallegos, Gary, Bridson, Lijun, Wu, Scott, Harbeson, Robert, Zelle, Roger, Tung

Publikováno v: Journal of mass spectrometry : JMS. 48(6)

Atazanavir (marketed as Reyataz®) is an important member of the human immunodeficiency virus protease inhibitor class. LC-UV-MS(n) experiments were designed to identify metabolites of atazanavir after incubations in human hepatocytes. Five major (M1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::65f5567b9ce8128715726a9d1f2f2975
https://pubmed.ncbi.nlm.nih.gov/23722954

Zobrazit plný text záznamu

Abstract 3357: CTP-221, a deuterated S-enantiomer of lenalidomide, is greatly stabilized to epimerization and results in a more desirable pharmacokinetic profile than racemic lenalidomide

Autor: Changfu Cheng, Ara M. Aslanian, Roger Tung, Vinita Uttamsingh, Julie Fields Liu, Richard Gallegos, Lijun Wu

Publikováno v: Cancer Research. 73:3357-3357

IMiD-class compounds, including thalidomide, lenalidomide, and pomalidomide, have been developed as racemic mixtures of S- and R-enantiomers. The isolated enantiomers of thalidomide are known to have distinct biological activities. For example, the w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c2b1238c8e73c5a6d32ccb164a352fa0
https://doi.org/10.1158/1538-7445.am2013-3357

Zobrazit plný text záznamu

Concert Pharmaceuticals Inc at JMP Securities Life Sciences Virtual Conference - Final

Publikováno v: Fair Disclosure Wire (Quarterly Earnings Reports). 06/16/2021.

Zobrazit plný text záznamu

Plný text ve formátu HTML

CTP-221, a Deuterated S-Enantiomer of Lenalidomide, Possesses Significantly Enhanced Immunomodulatory and Anti-Proliferative Properties Relative to the R-Enantiomer and to Racemic Lenalidomide

Autor: Roger Tung, Ara M. Aslanian, Kristine Hogan, Julie F. Liu, Lijun Wu

Publikováno v: Blood. 120:2463-2463

Abstract 2463 Lenalidomide (Revlimid®) is an immunomodulatory drug (IMiD) currently approved for the treatment of 5q- myelodysplastic syndrome and multiple myeloma. The clinical efficacy of lenalidomide is thought to be related in part to enhanced T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f58e01f38e269404b7b4f1ece1c685f1
https://doi.org/10.1182/blood.v120.21.2463.2463

Zobrazit plný text záznamu